WebJan 30, 2024 · Another option could include daratumumab, lenalidomide, and dexamethasone (DRd) continued until disease progression based on the MAIA trial showing improved progression-free survival and overall survival compared to Lenalidomide and Dexamethasone. [18] This may be particularly helpful in patients ineligible for bortezomib … WebApr 12, 2024 · CHICAGO--(BUSINESS WIRE)-- MAIA Biotechnology, Inc. (NYSE American: MAIA) today announced that it will present a poster that will feature the design of its ongoing Phase 2 clinical trial, THIO-101 evaluating THIO in patients with advanced Non-Small Cell Lung Cancer (NSCLC).The poster will be presented at the American Association for …
Ajai Chari, MD, Talks Diversity in Multiple Myeloma Research
WebJul 1, 2024 · Dr. Thierry Facon (Lille University Hospital, Lille, France) discusses the results of the MAIA study which compared the overall survival results in transplant-ineligible … WebNov 12, 2024 · The MAIA trial was a phase III trial comparing daratumumab, lenalidomide and dexamethasone (DRd) with lenalidomide and dexamethasone (Rd) for transplant … hp badge
Janssen Announces Results from Phase 3 MAIA Study Showing …
WebSep 30, 2014 · Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival … WebApr 29, 2024 · The MAIA study has proven and has been published in peer-reviewed literature to be a regimen that provides superiority when it comes to response rate, progression-free survival, and overall survival. We have overall survival that clearly exceeds 5 years and, in our previous simulation, it could be 9 or 10 years for patients … Web2 days ago · Abstract Number: CT050 / 8. Session Date: Monday, April 17, 2024, 9:00 am to 12:30 pm ET. Speaker/Lead Author: Mihail Obrocea, MD, MAIA’s Chief Medical Officer. Clinical trial abstract texts will be published online on AACR’s Online Itinerary Planner at 12:00 pm ET on April 14, 2024. fernán gonzález 42